A Phase Ib Study to Investigate the Safety, Tolerability and Preliminary Antitumor Activity of Gentuximab in Combination With Almonertinib in Patients With EGFR Mutation-positive Metastatic Non-Small Cell Lung Cancer
Latest Information Update: 05 Feb 2024
At a glance
- Drugs Aumolertinib (Primary) ; Gentuximab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors GeneScience Pharmaceuticals
Most Recent Events
- 08 Feb 2022 New trial record